Dabur Pharma forays into US Oncology market

New Delhi, May 9 (UNI) Oncology drug maker Dabur Pharma today said it has set up a subsidiary company in the US, directly responsible for sales, marketing and distribution of cancer products there.

The incorporation of Dabur Pharma's US subsidiary comes close on the heels of the suspension of sales and distribution agreement entered with Hospira Inc.

On May 5, Dabur Pharma terminated the sales and distribution agreement entered into between Dabur Oncology Plc and Hospira Inc for exclusive supply of oncology (cancer) products in the US.

''Going forward the company will sell and distribute its entire range of oncology products in the US through its own infrastructure,'' the company had said.

Dabur Oncology Plc, a wholly-owned subsidiary of Dabur Pharma in UK, has incorporated the US subsidiary company for marketing oncology products, Dabur Pharma said in a statement.

Dabur has also received the USFDA nod for selling two drugs, namely Paclitaxel and Carboplatin in the US, which constitutes about 50 per cent of the global oncology market.

The company is a market leader in the oncology segment in India.

It sold its domestic non-oncology formulations business to Alembic Ltd in January this year in line with its strategy to focus on core oncology business.

Oncology is the branch of medicine that studies tumors (cancer) and seeks to understand their development, diagnosis, treatment and prevention.

UNI